- Home
- OPP vs NTHI Comparison
OPP vs NTHI Comparison
Compare OPP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPP
- NTHI
- Stock Information
- Founded
- OPP 2010
- NTHI 2008
- Country
- OPP United States
- NTHI United States
- Employees
- OPP N/A
- NTHI N/A
- Industry
- OPP Finance/Investors Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- OPP Finance
- NTHI Health Care
- Exchange
- OPP Nasdaq
- NTHI Nasdaq
- Market Cap
- OPP 204.0M
- NTHI 211.9M
- IPO Year
- OPP N/A
- NTHI N/A
- Fundamental
- Price
- OPP $8.27
- NTHI $10.35
- Analyst Decision
- OPP
- NTHI
- Analyst Count
- OPP 0
- NTHI 0
- Target Price
- OPP N/A
- NTHI N/A
- AVG Volume (30 Days)
- OPP 108.0K
- NTHI 58.8K
- Earning Date
- OPP 01-01-0001
- NTHI 11-19-2025
- Dividend Yield
- OPP 14.41%
- NTHI N/A
- EPS Growth
- OPP N/A
- NTHI N/A
- EPS
- OPP N/A
- NTHI N/A
- Revenue
- OPP N/A
- NTHI $59,990.00
- Revenue This Year
- OPP N/A
- NTHI N/A
- Revenue Next Year
- OPP N/A
- NTHI N/A
- P/E Ratio
- OPP N/A
- NTHI N/A
- Revenue Growth
- OPP N/A
- NTHI N/A
- 52 Week Low
- OPP $7.26
- NTHI $3.20
- 52 Week High
- OPP $8.83
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- OPP 37.88
- NTHI N/A
- Support Level
- OPP $8.22
- NTHI N/A
- Resistance Level
- OPP $8.42
- NTHI N/A
- Average True Range (ATR)
- OPP 0.10
- NTHI 0.00
- MACD
- OPP -0.02
- NTHI 0.00
- Stochastic Oscillator
- OPP 31.58
- NTHI 0.00
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).